On July 17, Biogen rose 5.03% in regular trading, trading at $207.24/share, with turnover of $162 million. The rebound follows a 7%+ decline in the prior session triggered by a Diranersen Phase 2 trial missing its primary endpoint.

On the news front, Canada's drug management agency formally recognized the clinical value of Leqembi and recommended its inclusion in public health insurance coverage for treating early Alzheimer's disease. Leqembi, co-developed by Biogen and Eisai, posted Q1 revenue of $168 million, up 74% year-over-year. The Canadian recommendation marks a key step toward broader patient access. Additionally, the FDA recently approved Leqembi's subcutaneous injection formulation for initiation dosing, offering a more convenient at-home alternative. Real-world data presented at AAIC 2026 showed over 75% of early Alzheimer's patients remained stable after an average of 17 months of treatment.

Multiple analysts have recently raised price targets on Biogen, with Cantor Fitzgerald setting a $237 target, Jefferies at $255, and Truist upgrading to Buy with a $235 target. The consensus average target stands at approximately $224. The company is scheduled to report Q2 earnings on July 29.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)